Momenta Phama (MNTA) Prices 14.516M Share Common Offering at $15.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Momenta Phama (MNTA) Announces Dr. Jane F. Barlow to Board
December 13, 2019 8:01 AM ESTMomenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced the appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of Directors.
Dr. Barlows expertise in market access and commercial pricing will be invaluable as we continue to develop our pipeline of novel autoimmune therapeutics, said Craig Wheeler,... More
Pre-Open Movers 12/11: (PTI) (OLLI) (PLAB) Higher (ITRM) (GME) (PLCE) Lower (more...)
December 11, 2019 9:19 AM ESTToday's Pre-Open Movers
Iterum Therapeutics plc (Nasdaq: ITRM) 46.2% LOWER; announced topline results from its Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial in complicated intra-abdominal infections (cIAI). The primary U.S. Food and Drug Administration (FDA) endpoint was clinical response on Day 28 in the micro-MITT population. In this population, the difference in outcomes was 4.7% with a 95% confidence interval on that difference of -10.3% to 1.0%. Non-inferiority required that the lower limit of the difference in the outcome rates be >-10% for FDA.
After-Hours Movers 12/10: (ASPU) (OLLI) (PLAY) Higher; (ITRM) (GME) (AQST) Lower (more...)
December 10, 2019 5:28 PM ESTToday's After-Hours Movers
Iterum Therapeutics plc (Nasdaq: ITRM) 38.6% LOWER; announced topline results from its Sulopenem for Resistant Enterobacteriaceae (SURE) 3 clinical trial in complicated intra-abdominal infections (cIAI). The primary U.S. Food and Drug Administration (FDA) endpoint was clinical response on Day 28 in the micro-MITT population. In this population, the difference in outcomes was 4.7% with a 95% confidence interval on that difference of -10.3% to 1.0%. Non-inferiority required that the lower limit of the difference in the outcome rates be >-10% for FDA.
GameStop (NYSE:... More
Momenta Phama (MNTA) Announces Proposed $200M Share Common Offering
December 10, 2019 4:05 PM ESTMomenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common stock. Momenta also expects to grant the underwriters of the offering an option to purchase up to an additional $30,000,000 of shares of... More
